Reference,Reference: DOI,Assay,Section,Pre-vaccine Infection,Vaccine,# Shots,Months,Host,Control,Control: NT50 Cmp,Control: NT50 GeoMean,Control: NT50 GSD,Variant,Variant: Pos,Variant: Mutations,# Results,Potency: NT50 Cmp,Potency: NT50 GeoMean,Potency: NT50 GSD,Fold Reduction: Cmp,Fold Reduction: Median
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,5832.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,3662.0,1.0,=,1.6
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1816.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,1510.0,1.0,=,1.2
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1087.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,451.0,1.0,=,2.4
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,874.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,410.0,1.0,=,2.1
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,843.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,694.0,1.0,=,1.2
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,650.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,353.0,1.0,=,1.8
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,5658.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,2607.0,1.0,=,2.2
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,4310.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,2081.0,1.0,=,2.1
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,3383.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,608.0,1.0,=,5.6
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,2292.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,1244.0,1.0,=,1.8
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,2247.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,1227.0,1.0,=,1.8
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,2071.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,2371.0,1.0,=,0.9
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1973.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,1188.0,1.0,=,1.7
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1865.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,972.0,1.0,=,1.9